JCF Intersections

JCF-Intersections invites submissions spanning original investigations, state-of-the-art reviews, and patient narratives. Join us in advancing multidisciplinary care. Information for Authors: bit.ly/40hRwt7 #Cardiology #HeartFailure

Have you invested time in a full peer review only to face rejection? Your next step is JCF-I Express: Court of Appeals. You can resubmit previously reviewed manuscripts (outside JCF), include prior reviews, and skip repeating the full process. 🔗 bit.ly/4fV1nOi

Editorial perspective📝: The fragility index may help contextualize trial results, but should it change how we interpret validity? Beyond stats alone, improving CS care will require stronger trial design, clinical pathways & coordinated systems of care. bit.ly/4vfAZmr

Analyzing the robustness of tMCS trials through the lens of the fragility index (FI) highlights the paucity of data supporting these interventions. 📉 DanGer Shock was the only + MCS trial, but with an FI of just 4. FI for adverse events was more robust! bit.ly/3RCr63M

Editorial perspective📝: Despite the rising burden of methamphetamine-associated HF, major gaps remain in guidelines, funding, advocacy & coordinated research efforts. The field needs infrastructure, collaboration & national focus. ⚠️ 🔗 bit.ly/4nUwcVf

New science🚨! Methamphetamine-associated HF research is growing rapidly, but collaboration remains fragmented. Publications⬆️nearly 10-fold since 2015, yet most author networks remain disconnected. Multi-institutional collaboration is the next frontier! bit.ly/4abxIwf

🔗 bit.ly/4o2aGOs

Anthracycline cardiotoxicity remains a major challenge in cardio-oncology. This meta-analysis suggests SGLT2i may reduce mortality, HF events, & arrhythmias in anthracycline-treated patients, with reassuring safety signals. A promising prevention strategy? 🫀 Link below 👇

New month. New conversations in heart failure. The May issue of JCF-Intersections is out now featuring fresh insights, expert perspectives, and meaningful discussion from across the field. onlinejcfi.org/current

🔗 bit.ly/3NzhViZ

Another view urges caution: CS care is time-sensitive, & assembling teams could delay treatment. Clear, evidence-based protocols may be just as important as the team itself. The future likely lies in combining structured pathways with multidisciplinary care.⚖️ 🧵👇

Should cardiogenic shock teams become the standard of care? It's up for debate!🫀 One viewpoint argues yes: multidisciplinary shock teams can streamline diagnosis, coordinate care & improve outcomes across institutions. Observational data support their impact. 🧵👇

tMCS (e.g., VA-ECMO) can save lives—but what if there’s no path forward? A new perspective examines the ethical challenge of the “bridge to nowhere” and explores concepts like dynamic consent, moral distress, distributive justice, and so much more⚖️🫀 🔗 bit.ly/41oRsrt

LVAD offers a stable platform to help patients overcome barriers to heart transplant. In one cohort, ~70% had modifiable barriers and 60% of these resolved at least one after LVAD, highlighting the role of multidisciplinary care.🫀📊 🔗 bit.ly/4uPEHUy

Cardiogenic shock → low CO & end-organ hypoperfusion. LV failure is common, but don’t miss other causes: valvular disease, mechanical MI complications, or RV failure. A systematic approach + bedside echo can rapidly guide diagnosis and escalation.🫀 🔗 bit.ly/4uPBSTs

JCF Intersections is out now! Where research meets perspective, and new ideas take shape across disciplines. Explore the latest 👉 onlinejcfi.org/current #HeartFailure #Cardiology

@noshreza @JasonKatzMD @SarahChuzi @JulieDoberne @ShahzebKhanMD @ElliottMillerMD @hcg_md @dranulala @robmentz 🔗 bit.ly/3ZmjsLp

A HFrEF polypill💊 could ⬆️ GDMT uptake, but prescriber prefs are unknown. Using a 5-stage mixed-methods process, researchers built a discrete choice experiment to test cardiologists’ prefs—work that will directly inform future HFrEF polypill clinical trials. Read more 👇

New science 🚨! In an analysis of centrifugal-flow LVAD trials, digoxin💊 users showed greater improvement in 6MWT 🚶 vs no digoxin (especially in older pts) with similar QOL & AE rates. Digoxin was also linked to better 4-yr survival in NICM pts. 🔗 bit.ly/4r5phsy